Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT).

Al-Hilaly YK, Pollack SJ, Rickard JE, Simpson M, Raulin AC, Baddeley T, Schellenberger P, Storey JMD, Harrington CR, Wischik CM, Serpell LC.

J Mol Biol. 2018 Aug 16. pii: S0022-2836(18)30560-6. doi: 10.1016/j.jmb.2018.08.010. [Epub ahead of print]

2.

A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy.

Schwab K, Frahm S, Horsley D, Rickard JE, Melis V, Goatman EA, Magbagbeolu M, Douglas M, Leith MG, Baddeley TC, Storey JMD, Riedel G, Wischik CM, Harrington CR, Theuring F.

Front Mol Neurosci. 2018 Jan 10;10:447. doi: 10.3389/fnmol.2017.00447. eCollection 2017.

3.

Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.

Wischik CM, Schelter BO, Wischik DJ, Storey JMD, Harrington CR.

J Alzheimers Dis. 2018;62(3):1287-1303. doi: 10.3233/JAD-170727.

4.

Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.

Frahm S, Melis V, Horsley D, Rickard JE, Riedel G, Fadda P, Scherma M, Harrington CR, Wischik CM, Theuring F, Schwab K.

Behav Brain Res. 2018 Feb 26;339:153-168. doi: 10.1016/j.bbr.2017.11.025. Epub 2017 Nov 24.

5.

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, Storey JMD, Harrington CR, Wischik CM.

J Alzheimers Dis. 2018;61(1):435-457. doi: 10.3233/JAD-170560.

6.

Alzheimer's Disease-like Paired Helical Filament Assembly from Truncated Tau Protein Is Independent of Disulfide Crosslinking.

Al-Hilaly YK, Pollack SJ, Vadukul DM, Citossi F, Rickard JE, Simpson M, Storey JMD, Harrington CR, Wischik CM, Serpell LC.

J Mol Biol. 2017 Nov 24;429(23):3650-3665. doi: 10.1016/j.jmb.2017.09.007. Epub 2017 Sep 15.

7.

Assays for the Screening and Characterization of Tau Aggregation Inhibitors.

Rickard JE, Horsley D, Wischik CM, Harrington CR.

Methods Mol Biol. 2017;1523:129-140.

PMID:
27975248
8.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM.

Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16.

10.

Monoaminergic neuropathology in Alzheimer's disease.

Šimić G, Babić Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, de Silva R, Di Giovanni G, Wischik CM, Hof PR.

Prog Neurobiol. 2017 Apr;151:101-138. doi: 10.1016/j.pneurobio.2016.04.001. Epub 2016 Apr 12. Review.

11.

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease.

Lai RY, Harrington CR, Wischik CM.

Biomolecules. 2016 Apr 8;6(2). pii: E19. doi: 10.3390/biom6020019.

12.

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models.

Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, Goatman K, Goatman EA, Deiana S, Close SP, Zabke C, Stamer K, Dietze S, Schwab K, Storey JM, Harrington CR, Wischik CM, Theuring F, Riedel G.

Behav Pharmacol. 2015 Jun;26(4):353-68. doi: 10.1097/FBP.0000000000000133.

13.

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.

Harrington CR, Storey JM, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM.

J Biol Chem. 2015 Apr 24;290(17):10862-75. doi: 10.1074/jbc.M114.616029. Epub 2015 Mar 10.

14.

The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease.

Flores-Rodríguez P, Ontiveros-Torres MA, Cárdenas-Aguayo MC, Luna-Arias JP, Meraz-Ríos MA, Viramontes-Pintos A, Harrington CR, Wischik CM, Mena R, Florán-Garduño B, Luna-Muñoz J.

Front Neurosci. 2015 Feb 11;9:33. doi: 10.3389/fnins.2015.00033. eCollection 2015.

15.

Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.

Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR.

J Alzheimers Dis. 2015;44(2):705-20. doi: 10.3233/JAD-142874.

PMID:
25550228
16.

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration.

Melis V, Zabke C, Stamer K, Magbagbeolu M, Schwab K, Marschall P, Veh RW, Bachmann S, Deiana S, Moreau PH, Davidson K, Harrington KA, Rickard JE, Horsley D, Garman R, Mazurkiewicz M, Niewiadomska G, Wischik CM, Harrington CR, Riedel G, Theuring F.

Cell Mol Life Sci. 2015 Jun;72(11):2199-222. doi: 10.1007/s00018-014-1804-z. Epub 2014 Dec 19.

17.

Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease.

Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM.

J Pharmacol Exp Ther. 2015 Jan;352(1):110-8. doi: 10.1124/jpet.114.219352. Epub 2014 Oct 15.

18.

Hypofractionated radiation treatment following mastectomy in early breast cancer: the Christchurch experience.

Ko DH, Norriss A, Harrington CR, Robinson BA, James ML.

J Med Imaging Radiat Oncol. 2015 Apr;59(2):243-7. doi: 10.1111/1754-9485.12242. Epub 2014 Oct 6.

PMID:
25287654
19.

Tau-aggregation inhibitor therapy for Alzheimer's disease.

Wischik CM, Harrington CR, Storey JM.

Biochem Pharmacol. 2014 Apr 15;88(4):529-39. doi: 10.1016/j.bcp.2013.12.008. Epub 2013 Dec 19. Review.

20.

Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function.

Wasik U, Schneider G, Mietelska-Porowska A, Mazurkiewicz M, Fabczak H, Weis S, Zabke C, Harrington CR, Filipek A, Niewiadomska G.

Neurobiol Aging. 2013 May;34(5):1380-8. doi: 10.1016/j.neurobiolaging.2012.11.007. Epub 2012 Dec 20.

PMID:
23260124
21.

The molecular pathology of Alzheimer's disease.

Harrington CR.

Neuroimaging Clin N Am. 2012 Feb;22(1):11-22, vii. doi: 10.1016/j.nic.2011.11.003. Review.

PMID:
22284730
22.

Stripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T.

Lavdas I, Seton HC, Harrington CR, Wischik CM.

MAGMA. 2011 Dec;24(6):331-7. doi: 10.1007/s10334-011-0273-8. Epub 2011 Aug 4.

PMID:
21814757
23.

A glimpse at the chemistry of GeH2 in solution. Direct detection of an intramolecular germylene-alkene π-complex.

Billone PS, Beleznay K, Harrington CR, Huck LA, Leigh WJ.

J Am Chem Soc. 2011 Jul 13;133(27):10523-34. doi: 10.1021/ja201190b. Epub 2011 Jun 20.

PMID:
21639137
24.

Activation of the mesostriatal reward pathway with exposure to ultraviolet radiation (UVR) vs. sham UVR in frequent tanners: a pilot study.

Harrington CR, Beswick TC, Graves M, Jacobe HT, Harris TS, Kourosh S, Devous MD Sr, Adinoff B.

Addict Biol. 2012 May;17(3):680-6. doi: 10.1111/j.1369-1600.2010.00312.x. Epub 2011 Apr 11.

PMID:
21481104
25.

Addictive-like behaviours to ultraviolet light among frequent indoor tanners.

Harrington CR, Beswick TC, Leitenberger J, Minhajuddin A, Jacobe HT, Adinoff B.

Clin Exp Dermatol. 2011 Jan;36(1):33-8. doi: 10.1111/j.1365-2230.2010.03882.x.

PMID:
20545951
26.

Unphosphorylated CsgD controls biofilm formation in Salmonella enterica serovar Typhimurium.

Zakikhany K, Harrington CR, Nimtz M, Hinton JC, Römling U.

Mol Microbiol. 2010 Aug;77(3):771-86. doi: 10.1111/j.1365-2958.2010.07247.x. Epub 2010 Jun 9.

27.

Tanning as a behavioral addiction.

Kourosh AS, Harrington CR, Adinoff B.

Am J Drug Alcohol Abuse. 2010 Sep;36(5):284-90. doi: 10.3109/00952990.2010.491883. Review.

PMID:
20545604
28.

Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe.

Mukaetova-Ladinska EB, Xuereb JH, Garcia-Sierra F, Hurt J, Gertz HJ, Hills R, Brayne C, Huppert FA, Paykel ES, McGee MA, Jakes R, Honer WG, Harrington CR, Wischik CM.

ScientificWorldJournal. 2009 Dec 16;9:1463-75. doi: 10.1100/tsw.2009.151.

29.

What is the molecular pathology that underlies hippocampal memory decline?

Harrington CR.

J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):703. doi: 10.1136/jnnp.2008.163907. No abstract available.

PMID:
19531682
30.

Acquired cutis laxa associated with heavy chain deposition disease.

Harrington CR, Beswick TC, Susa JS, Pandya AG.

J Am Acad Dermatol. 2008 Nov;59(5 Suppl):S99-101. doi: 10.1016/j.jaad.2008.05.007.

PMID:
19119136
31.

A short-oligonucleotide microarray that allows improved detection of gastrointestinal tract microbial communities.

Harrington CR, Lucchini S, Ridgway KP, Wegmann U, Eaton TJ, Hinton JC, Gasson MJ, Narbad A.

BMC Microbiol. 2008 Nov 11;8:195. doi: 10.1186/1471-2180-8-195.

32.

Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine.

Deiana S, Harrington CR, Wischik CM, Riedel G.

Psychopharmacology (Berl). 2009 Jan;202(1-3):53-65. doi: 10.1007/s00213-008-1394-2. Epub 2008 Nov 14.

PMID:
19005644
33.

Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints.

Luna-Muñoz J, Peralta-Ramirez J, Chávez-Macías L, Harrington CR, Wischik CM, Mena R.

Acta Neuropathol. 2008 Nov;116(5):507-15. doi: 10.1007/s00401-008-0431-x. Epub 2008 Sep 23.

PMID:
18810470
34.

Evaluation of new tumors in the setting of stage I/IIA mycosis fungoides.

Harrington CR, Guillén DR, Pandya AG.

Clin Lymphoma Myeloma. 2007 Jul;7(7):480-5.

PMID:
17875239
35.
36.

Direct detection of dimethylstannylene and tetramethyldistannene in solution and the gas phase by laser flash photolysis of 1,1-dimethylstannacyclopent-3-enes.

Becerra R, Gaspar PP, Harrington CR, Leigh WJ, Vargas-Baca I, Walsh R, Zhou D.

J Am Chem Soc. 2005 Dec 14;127(49):17469-78.

PMID:
16332099
38.

Organogermanium reactive intermediates. The direct detection and characterization of transient germylenes and digermenes in solution.

Leigh WJ, Harrington CR, Vargas-Baca I.

J Am Chem Soc. 2004 Dec 15;126(49):16105-16. Erratum in: J Am Chem Soc. 2006 Feb 1;128(4):1394.

PMID:
15584746
39.

Extraocular sebaceous carcinoma in a patient with Muir-Torre syndrome.

Harrington CR, Egbert BM, Swetter SM.

Dermatol Surg. 2004 May;30(5):817-9.

PMID:
15099333
40.

Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics.

Mukaetova-Ladinska E, Hurt J, Honer WG, Harrington CR, Wischik CM.

Neurosci Lett. 2002 Jan 14;317(3):161-5.

PMID:
11755264
41.
42.

Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM.

Am J Pathol. 2000 Aug;157(2):623-36.

43.

Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease.

Maruyama H, Toji H, Harrington CR, Sasaki K, Izumi Y, Ohnuma T, Arai H, Yasuda M, Tanaka C, Emson PC, Nakamura S, Kawakami H.

Arch Neurol. 2000 Feb;57(2):236-40.

PMID:
10681083
44.

The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies.

Xu W, Liu L, Emson P, Harrington CR, McKeith IG, Perry RH, Morris CM, Charles IG.

Neuroreport. 2000 Feb 7;11(2):297-9.

PMID:
10674474
45.

Susceptibility genetics in the etiopathogenesis of Alzheimer's disease: role for potential confounding factors.

Harrington CR, Roth M.

Int Psychogeriatr. 1997 Sep;9(3):229-44. Review. No abstract available.

PMID:
9513025
46.
47.

Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein.

Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM.

Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):288-95.

PMID:
9298630
48.

Presenilin-1 intron 8 polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease.

Tysoe C, Whittaker J, Cairns NJ, Atkinson PF, Harrington CR, Xuereb J, Wilcock G, Rubinsztein DC.

Neurosci Lett. 1997 Jan 24;222(1):68-9.

PMID:
9121726
49.

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11213-8.

50.

Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population.

Brayne C, Harrington CR, Wischik CM, Huppert FA, Chi LY, Xuereb JH, O'Connor DW, Paykel ES.

Dementia. 1996 May-Jun;7(3):169-74. Review.

PMID:
8740632

Supplemental Content

Loading ...
Support Center